Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the month of February 2020. The report details a specific corporate action involving the transfer of treasury shares to satisfy employee equity awards under the company's Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific share transaction:
- Shares Transferred: 25,800,000 Ordinary Shares (25 pence each).
- ADRs Issued: 12,900,000 American Depositary Receipts.
- Consideration Received: $43.95 per ADR ($21.975 per Ordinary Share).
- Funding Source: Contribution to the Trust from GlaxoSmithKline LLC.
Material Changes
Following the transfer of treasury shares on February 10, 2020, the company's capital structure was updated as follows:
- Issued Share Capital: 5,384,119,172 Ordinary Shares.
- Treasury Shares Held: 367,705,950 Ordinary Shares.
- Total Voting Rights: 5,016,413,222.
This figure serves as the denominator for shareholders calculating notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risks, contingencies, or unusual items beyond the routine execution of the share transfer.
Investor Verification Checklist
- Verify the updated total number of voting rights (5,016,413,222) for compliance with disclosure thresholds.
- Confirm the reduction in treasury shares held by the company to 367,705,950.
- Review the specific terms of the Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan to understand the volume of awards satisfied by this transaction.